(0.31%) 5 116.01 points
(0.30%) 38 353 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.34%) $2 355.20
(0.56%) $27.69
(4.23%) $961.15
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology...
Stats | |
---|---|
本日の出来高 | 34 555.00 |
平均出来高 | 99 912.00 |
時価総額 | 44.52M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.280 |
ATR14 | $0.00700 (0.85%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
INSIDER POWER |
---|
77.72 |
Last 100 transactions |
Buy: 4 191 625 | Sell: 429 500 |
ボリューム 相関
Cytosorbents Corp 相関
10 最も正の相関 | |
---|---|
PRQR | 0.959 |
KIN | 0.958 |
SRRA | 0.949 |
NLSP | 0.947 |
BTWNU | 0.943 |
PROF | 0.941 |
GENQ | 0.94 |
ALXN | 0.939 |
RILYH | 0.938 |
IDCC | 0.932 |
10 最も負の相関 | |
---|---|
ZENV | -0.95 |
GRIN | -0.949 |
UTME | -0.948 |
NCBS | -0.945 |
THMA | -0.942 |
PDBC | -0.939 |
RIVN | -0.938 |
SNPX | -0.934 |
SOPA | -0.93 |
NAKD | -0.928 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cytosorbents Corp 相関 - 通貨/商品
Cytosorbents Corp 財務諸表
Annual | 2023 |
収益: | $36.35M |
総利益: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2023 |
収益: | $36.35M |
総利益: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2022 |
収益: | $29.36M |
総利益: | $15.40M (52.47 %) |
EPS: | $-0.750 |
FY | 2021 |
収益: | $43.17M |
総利益: | $32.12M (74.41 %) |
EPS: | $-0.570 |
Financial Reports:
No articles found.
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。